| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Association of Thrombocytopenia With Disease Burden, High-Risk Cytogenetics, and Survival in Newly Diagnosed Multiple Myeloma Patients Treated With Novel Therapies
|
Charalampous, Charalampos
|
|
|
24 |
10 |
p. e329-e335
|
article
|
| 2 |
Clinical Characteristics and Outcomes of CML in Adolescents and Young Adults
|
Al-rabi, Kamal
|
|
|
24 |
10 |
p. 715-723
|
article
|
| 3 |
Clinical Management of Patients With Relapsed/Refractory Multiple Myeloma Treated With Talquetamab
|
Chari, Ajai
|
|
|
24 |
10 |
p. 665-693.e14
|
article
|
| 4 |
Detection of PNH Clones can Aid in the Distinction of Aplastic Anemia vs Inherited BM Failure Syndromes: A Single Center Experience and Review of the Literature
|
Nasnas, Patrice
|
|
|
24 |
10 |
p. 732-735
|
article
|
| 5 |
Editorial Board
|
|
|
|
24 |
10 |
p. A6-A7
|
article
|
| 6 |
Efficacy of Chemotherapy-Free Regimens in the Treatment of Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia: A Systematic Review and Meta-Analysis
|
Ali, Muhammad Ashar
|
|
|
24 |
10 |
p. e376-e384
|
article
|
| 7 |
Impact of Facility Type on Survival in Chronic Myelomonocytic Leukemia: A Propensity Score Matched, National Cancer Database Analysis
|
Tharakan, Serena
|
|
|
24 |
10 |
p. e385-e391.e1
|
article
|
| 8 |
Nivolumab, Pomalidomide, and Elotuzumab Combination Regimens for Treatment of Relapsed and Refractory Multiple Myeloma: Results from the Phase 3 CheckMate 602 Study
|
Oriol, Albert
|
|
|
24 |
10 |
p. 703-714
|
article
|
| 9 |
Overview of Research Status in Castleman Disease
|
Wang, Wenqiu
|
|
|
24 |
10 |
p. e359-e365
|
article
|
| 10 |
Phase I Trial of Brentuximab Vedotin Plus Cyclosporine in Relapsed/Refractory Hodgkin Lymphoma
|
Thiruvengadam, Swetha Kambhampati
|
|
|
24 |
10 |
p. 724-731.e1
|
article
|
| 11 |
Real-World Treatment Patterns, Survival, and Economic Burden Among Elderly MCL Patients Previously Treated With cBTKis
|
Squires, Patrick
|
|
|
24 |
10 |
p. e350-e358.e1
|
article
|
| 12 |
Risk of Secondary Malignancies After Multiple Myeloma: A Nationwide Case-Control Cohort Study
|
Ko, Heejoo
|
|
|
24 |
10 |
p. e366-e375
|
article
|
| 13 |
SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma
|
Schmidt, Timothy
|
|
|
24 |
10 |
p. 653-664
|
article
|
| 14 |
SOHO State of the Art Updates and Next Questions Updates on Building Your CAR-T Cell Program
|
Voorhees, Timothy J.
|
|
|
24 |
10 |
p. 649-652
|
article
|
| 15 |
Table of Contents
|
|
|
|
24 |
10 |
p. A9-A11
|
article
|
| 16 |
The Effect of Age and Other Patient Characteristics on Outcomes Among Nontransplanted Patients Who Were Treated With First-Line Lenalidomide, Bortezomib, and Dexamethasone: Results From the ConnectⓇ MM Registry
|
Abonour, Rafat
|
|
|
24 |
10 |
p. e336-e343
|
article
|
| 17 |
The Glass Wall: Gendered Authorship Disparities in CD 19 and BCMA CAR-T Clinical Trials for Lymphoma and Myeloma
|
Khaliq, Aroog
|
|
|
24 |
10 |
p. e344-e349
|
article
|
| 18 |
The Real-World Data on Patients With Cardiac Stage IIIb AL Amyloidosis
|
Hong, Yi
|
|
|
24 |
10 |
p. 694-702
|
article
|
Journal description